Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Assets (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Current Assets for 15 consecutive years, with $426.0 million as the latest value for Q1 2026.

  • For Q1 2026, Current Assets fell 2.84% year-over-year to $426.0 million; the TTM value through Mar 2026 reached $426.0 million, down 2.84%, while the annual FY2025 figure was $485.5 million, 2.94% up from the prior year.
  • Current Assets hit $426.0 million in Q1 2026 for Corcept Therapeutics, down from $485.5 million in the prior quarter.
  • Across five years, Current Assets topped out at $560.8 million in Q2 2024 and bottomed at $388.2 million in Q1 2022.
  • Average Current Assets over 5 years is $467.8 million, with a median of $458.6 million recorded in 2023.
  • Year-over-year, Current Assets soared 87.36% in 2022 and then decreased 20.99% in 2025.
  • Corcept Therapeutics' Current Assets stood at $499.3 million in 2022, then fell by 8.14% to $458.6 million in 2023, then increased by 2.83% to $471.6 million in 2024, then rose by 2.94% to $485.5 million in 2025, then fell by 12.24% to $426.0 million in 2026.
  • According to Business Quant data, Current Assets over the past three periods came in at $426.0 million, $485.5 million, and $541.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.